Key Points
- Director David Morton Fox bought 3,537 shares of MediWound at $14.11 each, a transaction worth about $49,907. After the purchase, he owned 22,283 shares, boosting his stake by 18.87%.
- MediWound reported a smaller-than-expected quarterly loss of ($0.23) EPS, beating estimates, but revenue of $1.48 million came in below forecasts of $3.37 million.
- Analyst sentiment is mixed but leans cautious: the stock has a Hold consensus rating and an average price target of $34, despite some firms still issuing Buy ratings.
MediWound Ltd. (NASDAQ:MDWD - Get Free Report) Director David Morton Fox purchased 3,537 shares of the stock in a transaction on Monday, June 1st. The stock was acquired at an average price of $14.11 per share, with a total value of $49,907.07. Following the completion of the acquisition, the director directly owned 22,283 shares of the company's stock, valued at approximately $314,413.13. This represents a 18.87% increase in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website.
MediWound Price Performance
Shares of MediWound stock opened at $13.76 on Wednesday. MediWound Ltd. has a 1 year low of $13.54 and a 1 year high of $22.48. The business has a 50-day moving average of $16.56 and a two-hundred day moving average of $17.40. The company has a market capitalization of $176.82 million, a P/E ratio of -6.09 and a beta of 0.16.
MediWound (NASDAQ:MDWD - Get Free Report) last announced its quarterly earnings results on Wednesday, May 27th. The biopharmaceutical company reported ($0.23) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.65) by $0.42. MediWound had a negative return on equity of 67.22% and a negative net margin of 180.30%.The company had revenue of $1.48 million during the quarter, compared to the consensus estimate of $3.37 million. During the same period in the prior year, the company earned ($0.07) earnings per share. On average, equities analysts anticipate that MediWound Ltd. will post -2.49 EPS for the current fiscal year.
Institutional Inflows and Outflows
A number of hedge funds have recently modified their holdings of MDWD. Quarry LP bought a new position in shares of MediWound during the fourth quarter worth about $26,000. BNP Paribas Financial Markets grew its holdings in shares of MediWound by 90.4% during the third quarter. BNP Paribas Financial Markets now owns 1,523 shares of the biopharmaceutical company's stock worth $27,000 after buying an additional 723 shares in the last quarter. Russell Investments Group Ltd. grew its holdings in shares of MediWound by 69.1% during the second quarter. Russell Investments Group Ltd. now owns 1,588 shares of the biopharmaceutical company's stock worth $31,000 after buying an additional 649 shares in the last quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. grew its holdings in shares of MediWound by 22.4% during the first quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 5,452 shares of the biopharmaceutical company's stock worth $85,000 after buying an additional 999 shares in the last quarter. Finally, MetLife Investment Management LLC bought a new position in shares of MediWound during the fourth quarter worth about $109,000. 46.83% of the stock is currently owned by institutional investors.
Analyst Upgrades and Downgrades
MDWD has been the subject of several recent analyst reports. Oppenheimer restated an "outperform" rating and issued a $32.00 price target (down from $33.00) on shares of MediWound in a report on Wednesday, May 27th. Wall Street Zen upgraded MediWound from a "strong sell" rating to a "sell" rating in a report on Saturday. Weiss Ratings reiterated a "sell (d-)" rating on shares of MediWound in a report on Tuesday, April 21st. Finally, HC Wainwright reiterated a "buy" rating and set a $36.00 price objective on shares of MediWound in a report on Thursday, May 28th. Two research analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the stock. Based on data from MarketBeat.com, MediWound has an average rating of "Hold" and a consensus target price of $34.00.
Get Our Latest Stock Analysis on MDWD
MediWound Company Profile
(
Get Free Report)
MediWound Ltd. (NASDAQ: MDWD) is a biopharmaceutical company headquartered in Yavne, Israel, specializing in the development and commercialization of innovative enzymatic therapies for burn and wound management. Since its establishment, the company has focused on advancing proteolytic enzyme technology to address critical needs in debridement and tissue repair. MediWound operates research and development facilities in Israel and maintains commercial offices in the United States to support its global market presence.
The company's lead product, NexoBrid®, is an enzyme-based debriding agent designed to selectively remove burn eschar without harming viable tissue.
Featured Articles
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
